Literature DB >> 14660593

Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion.

Christopher B Doering1, John F Healey, Ernest T Parker, Rachel T Barrow, Pete Lollar.   

Abstract

Blood coagulation factor VIII has a domain structure designated A1-A2-B-ap-A3-C1-C2. Human factor VIII is present at low concentration in normal plasma and, comparably, is produced at low levels in vitro and in vivo using transgenic expression techniques. Heterologous expression of B domain-deleted porcine factor VIII in mammalian cell culture is significantly greater than B domain-deleted human or murine factor VIII. Novel hybrid human/porcine factor VIII molecules were constructed to identify porcine factor VIII domains that confer high level expression. Hybrid human/porcine factor VIII constructs containing the porcine factor VIII A1 and ap-A3 domains expressed at levels comparable with recombinant porcine factor VIII. A hybrid construct containing only the porcine A1 domain expressed at intermediate levels between human and porcine factor VIII, whereas a hybrid construct containing the porcine ap-A3 domain expressed at levels comparable with human factor VIII. Additionally, hybrid murine/porcine factor VIII constructs containing the porcine factor VIII A1 and ap-A3 domain sequences expressed at levels significantly higher than recombinant murine factor VIII. Therefore, the porcine A1 and ap-A3 domains are necessary and sufficient for the high level expression associated with porcine factor VIII. Metabolic radiolabeling experiments demonstrated that high level expression was attributable to enhanced secretory efficiency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660593     DOI: 10.1074/jbc.M312451200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.

Authors:  Ernest T Parker; Pete Lollar
Journal:  Biochemistry       Date:  2007-08-04       Impact factor: 3.162

2.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

3.  Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.

Authors:  P M Zakas; K Vanijcharoenkarn; R C Markovitz; S L Meeks; C B Doering
Journal:  J Thromb Haemost       Date:  2014-11-11       Impact factor: 5.824

4.  Advancements in gene transfer-based therapy for hemophilia A.

Authors:  Christopher B Doering; H Trent Spencer
Journal:  Expert Rev Hematol       Date:  2009-12       Impact factor: 2.929

5.  Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response.

Authors:  Harrison C Brown; Bagirath Gangadharan; Christopher B Doering
Journal:  J Biol Chem       Date:  2011-05-23       Impact factor: 5.157

Review 6.  Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells.

Authors:  Christopher B Doering; David Archer; H Trent Spencer
Journal:  Adv Drug Deliv Rev       Date:  2010-09-30       Impact factor: 15.470

7.  Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A.

Authors:  Philip M Zakas; H Trent Spencer; Christopher B Doering
Journal:  J Genet Syndr Gene Ther       Date:  2011-11-16

8.  Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.

Authors:  Joshua I Siner; Nicholas P Iacobelli; Denise E Sabatino; Lacramiora Ivanciu; Shangzhen Zhou; Mortimer Poncz; Rodney M Camire; Valder R Arruda
Journal:  Blood       Date:  2013-01-31       Impact factor: 22.113

9.  The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.

Authors:  John F Healey; Ernest T Parker; Rachel T Barrow; Travis J Langley; William R Church; Pete Lollar
Journal:  Thromb Haemost       Date:  2009-07       Impact factor: 5.249

10.  Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.

Authors:  Kerry L Dooriss; Gabriela Denning; Bagirath Gangadharan; Elisabeth H Javazon; David A McCarty; H Trent Spencer; Christopher B Doering
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.